You just read:

Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility

News provided by

Merrimack Pharmaceuticals, Inc.

Oct 19, 2018, 06:00 ET